A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Patients with Facioscapulohumeral Muscular Dystrophy

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Locations

Brain Imaging Center (BIC)
Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Photograph of Matthew Wicklund,  MD

Matthew Wicklund, MD

Study ID

Protocol Number: 22-1143

More information available at ClinicalTrials.gov: NCT05397470

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers